Ginkgo biloba extract induces gene expression changes in xenobiotics metabolism and the myc-centered network

OMICS A Journal of Integrative Biology

Volumn 14, Issue 1, 2010, Pages 75-90

  Guo, Lei ^a   Mei, Nan ^a   Liao, Wayne ^b   Chan, Po Chuen ^c   Fu, Peter P ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b PhalanxBio Inc   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLIZING ENZYME; GINKGO BILOBA EXTRACT; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; CELL CYCLE; CELL MOTION; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION PROFILING; LIVER TOXICITY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE MYC; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; XENOBIOTIC METABOLISM;

ANIMALS; GENE EXPRESSION; GENES, MYC; GINKGO BILOBA; MALE; MICE; PLANT EXTRACTS; POLYMERASE CHAIN REACTION; XENOBIOTICS;

ANIMALIA; GINKGO BILOBA; MUS; RODENTIA;

EID: 77049094690     PISSN: 15362310     EISSN: None     Source Type: Journal    
DOI: 10.1089/omi.2009.0115     Document Type: Article

References (58)

1. Aleksunes, L.M., and Manautou, J.E. (2007). Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol Pathol 35, 459-473.
2. Beer, S., Komatsubara, K., Bellovin, D.I., Kurobe, M., Sylvester, K., and Felsher, D.W. (2008). Hepatotoxin-induced changes in the adult murine liver promote MYC-induced umorigenesis. PLoS ONE 3, e2493.
3. Blomme, E.A., Yang, Y., and Waring, J.F. (2009). Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol Lett 186, 22-31.
4. Borlak, J., Meier, T., Halter, R., Spanel, R., and Spanel-Borowski, K. (2005). Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 24, 1809-1819.
5. Bressler, R. (2005). Herb-drug interactions: interactions between kava and prescription medications. Geriatrics 60, 24-25. (Pubitemid 41318296)
6. Brunnberg, S., Andersson, P., Lindstam, M., Paulson, I., Poellinger, L., and Hanberg, A. (2006). The constitutively active Ah receptor (CA-Ahr) mouse as a potential model for dioxin exposure- effects in vital organs. Toxicology 224, 191-201.
7. Chan, K., Han, X.D., and Kan, Y.W. (2001). An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci USA 98, 4611-4616.
8. Chan, P.C., and Fu, P.P. (2007). Toxicity of Panax ginseng-An herbal medicine and dietary supplements. J Food Drug Anal 15, 416-427.
9. Chan, P.C., Xia, Q., and Fu, P.P. (2007). Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25, 211-244.
10. Chandar, N., Lombardi, B., and Locker, J. (1989). c-Myc gene amplification during hepatocarcinogenesis by a choline-devoid diet. Proc Natl Acad Sci USA 86, 2703-2707.
11. Chen, H., Liu, J., Zhao, C.Q., Diwan, B.A., Merrick, B.A., and Waalkes, M.P. (2001). Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol Appl Pharmacol 175, 260-268.
12. Ciraulo, D.A., Shader, R.I., Greenblatt, D.J., and Creelman, W. (2005). Drug Interaction in Psychiatry. (Lippincott Williams & Wilkins, Philaldephia, PA).
13. Clayton, N.P., Yoshizawa, K., Kissling, G.E., Burka, L.T., Chan, P.C., and Nyska, A. (2007). Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. Exp Toxicol Pathol 58, 223-236.
14. Clouatre, D.L. (2004). Kava kava: examining new reports of toxicity. Toxicol Lett 150, 85-96.
15. Dang, C.V. (1999). c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19, 1-11.
16. Dubey, A.K., Shankar, P.R., Upadhyaya, D., and Deshpande, V.Y. (2004). Ginkgo biloba-an appraisal. Kathmandu Univ Med J 2, 225-229.
17. FDA. (2001). FDA advises dietary supplement manufacturers to remove comfrey products from the market. July 6, 2001. Available at: http:==www.cfsan.fda.gov=*dms=supplmnt. html.
18. FDA(2004a). FDA Public Health News, FDA announced major initiatives for dietary supplements. November 5, 2004.
19. FDA. (2004). Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk federal register. February 11, 2004.
20. Fong, H.H. (2002). Integration of herbal medicine into modern medical practices: issues and prospects. Integr Cancer Ther 1, 287-293.
21. Fu, P.P. (2007). Quality assurance and safety of herbal dietary supplements. J Food Drug Anal 15, 333-334.
22. Fu, P.P., Yang, Y.C., Xia, Q., Chou, M.W., Cui, Y.Y., and Lin, G. (2002). Pyrrolizidine alkaloids-tumorigenic components in Chinese herbal medicines and dietary supplements. J Food Drug Anal 10, 198-211.
23. Fu, P.P., Xia, Q., Chou, M.W., and Lin, G. (2007). Detection, hepatotoxicity, and tumorigenicity of pyrrolizidine alkaloids in Chinese herbal plants and herbal dietary supplemnets. J Food Drug Anal 15, 400-415.
24. Fu, P.P., Xia, Q., Guo, L., Yu, H., and Chan, P.C. (2008). Toxicity of kava kava. J Environ Sci Health Part C 26, 89-112.
25. Gonzalez, F.J., and Gelboin, H.V. (1994). Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26, 165-183.
26. Gonzalez, F.J., and Yu, A.M. (2006). Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol 46, 41-64.
27. Guo, L., Lobenhofer, E.K., Wang, C., Shippy, R., Harris, S.C., Zhang, L., et al. (2006). Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol 24, 1162-1169.
28. Guo, L., Li, Q., Xia, Q., Dial, S., Chan, P.C., and Fu, P. (2009). Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract. Food Chem Toxicol 47, 433-442.
29. Gurley, B.J., Gardner, S.F., Hubbard, M.A., Williams, D.K., Gentry, W.B., Carrier, J., et al. (2004). In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 76, 428-440.
30. Gurley, B.J., Gardner, S.F., Hubbard, M.A., Williams, D.K., Gentry, W.B., Cui, Y., et al. (2005). Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 22, 525-539.
31. Gurley, B.J., Swain, A., Barone, G.W., Williams, D.K., Breen, P., Yates, C.R., et al. (2007). Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 35, 240-245.
32. Harvey, C.J., Thimmulappa, R.K., Singh, A., Blake, D.J., Ling, G., Wakabayashi, N., et al. (2009). Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic Biol Med 46, 443-453.
33. Hu, Z., Yang, X., Ho, P.C., Chan, S.Y., Heng, P.W., Chan, E., et al. (2005). Herb-drug interactions: a literature review. Drugs 65, 1239-1282.
34. Iyer, K.R., and Sinz, M.W. (1999). Characterization of Phase I and Phase II hepatic drug metabolism activities in a panel of human liver preparations. Chem Biol Interact 118, 151-169.
35. Kensler, T.W., Wakabayashi, N., and Biswal, S. (2007). Cell survival responses to environmental stresses via the Keap1- Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47, 89-116.
36. Klick, D.E., and Hines, R.N. (2007). Mechanisms regulating human FMO3 transcription. Drug Metab Rev 39, 419-442.
37. Lee, T.C., Li, L., Philipson, L., and Ziff, E.B. (1997). Myc represses transcription of the growth arrest gene gas1. Proc Natl Acad Sci USA 94, 12886-12891.
38. Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408.
39. Martignoni, M., Groothuis, G.M., and De Kanter, R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2, 875-894.
40. Matthias, A., Blanchfield, J.T., Penman, K.G., Bone, K.M., Toth, I., and Lehmann, R.P. (2007). Permeability studies of Kavalactones using a Caco-2 cell monolayer model. J Clin Pharm Ther 32, 233-239.
41. Nie, A.Y., McMillian, M., Parker, J.B., Leone, A., Bryant, S., Yieh, L., et al. (2006). Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol Carcinog 45, 914-933.
42. NTP,1998 Nomination of Ginkgo biloba extract, Available at: http:==ntp.niehs.nih.gov=?objectid=BDCABE80-123F-7908-7BF75015B4AC13D.
43. Parte, P., and Kupfer, D. (2005). Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos 33, 1446-1452.
44. Pelengaris, S., Khan, M., and Evan, G. (2002). c-MYC: more than just a matter of life and death. Nat Rev Cancer 2, 764-776.
45. Ramos-Gomez, M., Kwak, M.K., Dolan, P.M., Itoh, K., Yamamoto, M., Talalay, P., et al. (2001). Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98, 3410-3415.
46. Rezen, T., Contreras, J.A., and Rozman, D. (2007). Functional genomics approaches to studies of the cytochrome p450 superfamily. Drug Metab Rev 39, 389-399.
47. Roymans, D., Van Looveren, C., Leone, A., Parker, J.B., McMillian, M., Johnson, M.D., et al. (2004). Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. Biochem Pharmacol 67, 427-437.
48. Sandgren, E.P., Quaife, C.J., Pinkert, C.A., Palmiter, R.D., and Brinster, R.L. (1989). Oncogene-induced liver neoplasia in transgenic mice. Oncogene 4, 715-724.
49. Shi, L., Reid, L.H., Jones, W.D., Shippy, R., Warrington, J.A., Baker, S.C., et al. (2006). The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24, 1151-1161.
50. Singh, Y.N. (2005). Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 100, 108-113.
51. Tusher, V.G., Tibshirani, R., and Chu, G. (2001). Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98, 5116-5121.
52. Wang, A., and Gehan, E.A. (2005). Gene selection for microarray data analysis using principal component analysis. Stat Med 24, 2069-2087.
53. Williamson, E.M. (2005). Interactions between herbal and conventional medicines. Expert Opin Drug Saf 4, 355-378.
54. Wold, R.S., Lopez, S.T., Yau, C.L., Butler, L.M., Pareo-Tubbeh, S.L., Waters, D.L., et al. (2005). Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. J AmDiet Assoc 105, 54-63.
55. Xu, C., Li, C.Y., and Kong, A.N. (2005). Induction of phase I, II and III drug metabolism=transport by xenobiotics. Arch Pharm Res 28, 249-268.
56. Zelko, I.N., Mariani, T.J., and Folz, R.J. (2002). Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 33, 337-349.
57. Zou, L., Harkey, M.R., and Henderson, G.L. (2002). Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 71, 1579-1589.
58. Zurer, P., and Hanson, D. (2004). Chemistry puts herbal supplements to the test. Chemical & Engineering News 82, 16.